Diabetic Macular Edema clinical trials

Explore recruiting diabetic macular edema clinical trials.

Recruiting diabetic macular edema studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Diabetic Macular Edema trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A RANDOMIZED, DOUBLE-MASKED, MULTI-CENTER, 3-ARM PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVITREAL EYE103 COMPARED WITH INTRAVITREAL RANIBIZUMAB (0.5MG) IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA

Italy, Germany, Latvia, Hungary, France, Czechia +6 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Randomized, Double-masked, Multi-center, 3-Arm Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal EYE103 Compared with Intravitreal ranibizumab (0.5mg) in Participants with Diabetic Macular Edema

Italy, Spain, Slovakia, Poland, Portugal, Croatia +6 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 3 Double-masked, Randomized, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema

Italy, France, Germany, Spain, Czechia, Bulgaria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multi-Center, Randomized, Parallel-Group, Phase 2, Masked, Three-Arm Trial to Compare Safety, Tolerability, Efficacy, and Durability of Two Dose Levels of Suprachoroidal Sustained-Release OXU-001 (Dexamethasone Microspheres; DEXAspheres®) Using the Oxulumis® Illuminated Microcatheterization Device Compared with Intravitreal Dexamethasone Implant (OZURDEX®) in Subjects with Diabetic Macular Edema (OXEYE).

Hungary, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-masked, Parallel-group, Multicenter Clinical Study to Evaluate the Efficacy and Safety of AVT29 Compared with Eylea High Dose (HD) in Participants with Diabetic Macular Edema (ALVOEYE-HD)

Latvia, Slovakia, Czechia, Hungary, Poland, Bulgaria

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2/3 Double-masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema

Spain, Hungary

Phase II and Phase III (Integrated) EU CTIS Study details

Diabetic Macular Edema trials by city

Diabetic Macular Edema in Toronto Diabetic Macular Edema in Vancouver Diabetic Macular Edema in Montreal Diabetic Macular Edema in Calgary Diabetic Macular Edema in Edmonton Diabetic Macular Edema in Ottawa Diabetic Macular Edema in Winnipeg Diabetic Macular Edema in Quebec City Diabetic Macular Edema in Hamilton Diabetic Macular Edema in Kitchener Diabetic Macular Edema in London Diabetic Macular Edema in Halifax Diabetic Macular Edema in New York Diabetic Macular Edema in Los Angeles Diabetic Macular Edema in Chicago Diabetic Macular Edema in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease